pain during anesthesia R52.9
Conditions
Interventions
Group 1: measurements without drug application about 30 minutes
after that measurements under 0,05 µg/kg/min remifentanil-infusion (i.v., continuously) about 40 minutes
in the course of the trail additional propofol-infusion until loss of consciousness (defined when volunteers stop squeezing the investigator's hand although requested)
occurs shortly after propofol-induction and persists by continuous i.v. propofol-infusion
duration of combined remifentail/propofol-infusion about 30 minutes
Group 2: measurements without drug application about 30 minutes
after that measurements under 0,10 µg/kg/min remifentanil-infusion (i.v., continuously) about 40 minutes
duration of combined remifentail/propofol-infusion about 30 minutes
Group 3: measurements without drug application about 30 minutes
after that measurements under 0,20 µg/kg/min remifentanil-infusion (i.v., continuously) about 40 minutes
duration of combined remifentail/propofol-infusion about 30 minutes
Group 4: measurements without drug application about 30 minutes
after that measurements under 0,40 µg/kg/min remifentanil-infusion (i.v., continuously) about 40 minutes
in the course of the trail additional propofol-infusion until loss of consciousness (defined when volunteers stop squeezing the i
Sponsors
Zentrum für Anästhesiologie, Helios Klinikum Wuppertal, Universität Witten/Herdecke
Eligibility
Sex/Gender
All
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: ASA physical status 1-2 (classification system to assess fitness of patients before surgery): correlates with healthy patients (ASA 1) and patients with mild systemic disease (ASA 2), written consent, mental capacity, age: 18-50 years
Exclusion criteria
Exclusion criteria: cardiac, hepatic, renal, pulmonary or gastrointestinal diseases, disorders of gastrointestinal motility, psychiatric and neurologic diseases, altered cerebral perfusion, chronic intake of drugs, psychotropics or other substances with central- or peripheral nervous effects, hypacusis and deafness, analgetic long-term medication, chronic pain, agitated or anxious patients, allergy, known intolerance and contraindications against the used drugs, pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| correlation between individual pain perception (described by visual analogue scale, VAS) and CHEP-amplitudes (Contact Heat Evoked Potentials) as the electroencephalographic correlate of the applied heat pain under remifentanil als analgesic. Remifentanil-induced changes of VAS and CHEP will be compared to the baseline measurement without drug application and will be analyzed under four different remifentanil-concentrations. | — |
Secondary
| Measure | Time frame |
|---|---|
| - correlation between remifentanil concentration and reduction of CHEP (Contact Heat Evoked Potential)-amplitudes - registration of potential sedative effects of remifentanil by AEP (auditory evoked potentials) and OAA/S-score (Observer's Assessment of Alertness/Sedation-score) - effects of loss of consciousness on CHEP (Contact Heat Evoked Potential) - gender-related differences on CHEP (Contact Heat Evoked Potential) | — |
Countries
Germany
Contacts
Public ContactGisela Untergehrer
Zentrum für Anästhesiologie, Helios Klinikum Wuppertal, Universität Witten/Herdecke
Outcome results
None listed